Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation
Kyntra Bio announced a significant amendment to its royalty financing agreement, reducing its maximum payment obligation from $125 million to $65 million through an accelerated $42.6 million upfront payment and a capped revenue-sharing arrangement. Alongside settling bankruptcy obligations of its European subsidiary, these actions have significantl…